
# What's new in Renal Supportive Care?

What's happened from Jan 2016 to now?



After much discussion, debate, and research, the Oxford Dictionaries Word of the Year 2016 is *post-truth* – an adjective defined as:

'relating to or denoting circumstances in which objective facts are less influential in shaping public opinion than appeals to emotion and personal belief'.

# 'Post-progress'

'Post-progress' suggests that technical ability and more and more interventions, while they extend wanted life for many, also bring with them existential quandaries about one's own relationship to medicine, to suffering, to more life, and of the apparent control that can be exercised over the timing of death.


-Sharon R. Kaufman, Kaufman, S.R. **Ordinary Medicine.** Duke University Press, Chapel Hill, NC; 2015



# Survival with Dialysis




Prevalent Dialysis Patients - Australia 31 December 2015



2016 ANZDATA Annual Report, Figure 2.7



#### Survival on Renal Replacement Therapy Australia 2006-2015



2016 ANZDATA Annual Report, Figure 3.1



### Dialysis Survival perspective – Australian Data

#### **Overall 5 year survival rates**


<ul> <li>prostate cancer</li> </ul>	92%	
<ul> <li>breast cancer</li> </ul>	89%	
<ul> <li>renal cancer</li> </ul>	72%	
RRT in Australia		
• aged 45-64	69%	
<ul> <li>bowel cancer</li> </ul>	66%	
Heart failure	52%	
<ul> <li>dialysis in Australia</li> </ul>		
• aged 65-74	48%	
ovarian cancer	43%	
<ul> <li>dialysis in Australia</li> </ul>		
• aged 75-84	33%	
<ul> <li>lung cancer</li> </ul>	< 14%	



Data from the Cancer Council of Australia (<u>www.cancer.org.au</u>) and ANZDATA 2016 (<u>www.anzdata.org.au</u>); Heart Failure from JAMA. 2004; 292(3):344.



Cause of death
Deaths occurring during 2015



2016 ANZDATA Annual Report, Figure 3.5

# Can we predict a patient's survival on dialysis?

Nephrol Dial Transplant (2017) 1-8 doi: 10.1093/ndt/gfw383




#### Original Article

# Predicting 6-month mortality risk of patients commencing dialysis treatment for end-stage kidney disease

Sara E. Ivory<sup>1</sup>, Kevan R. Polkinghorne<sup>1,2</sup>, Yeasmin Khandakar<sup>1</sup>, Jessica Kasza<sup>1</sup>, Sophia Zoungas<sup>3</sup>, Retha Steenkamp<sup>4</sup>, Paul Roderick<sup>5</sup> and Rory Wolfe<sup>1</sup>

Monash, Australia, and UK data

- Developed model based on ANZDATA patients ≥15 yrs. old 2000 2009
- Validated based on ANZDATA 2009-2011
- External validation using UK renal registry



**FIGURE 1:** Selection of patients for inclusion in risk prediction model development.

#### 6% died within 6 months

- older
- More co-morbidities

# Factors in predictive model

- 1. Older age
- 2. Underweight
- 3. COPD
- 4. PVD
- 5. Cerebrovascular disease (esp. age < 60)
- Performed better than some other models and useful for Australian data but not validated externally

# Do patient-reported measures of symptoms and health status predict mortality in hemodialysis? An assessment of POS-S Renal and EQ-5D

Donal J. SEXTON, 1,\* Aoife C. LOWNEY, 2,\* Conall M. O'SEAGHDHA, Marie MURPHY, Tony O'BRIEN, Liam F. CASSERLY, Regina MCQUILLAN, William D. PLANT, Joseph A. EUSTACE, 6,7 Sinead M. KINSELLA, Peter J. CONLON

<sup>1</sup>Health Research Board of Ireland Clinical Research Facility, National University of Ireland Galway, Galway, Ireland; <sup>2</sup>Department of Palliative Medicine, Marymount University Hospital & Hospice, Cork, Ireland; <sup>3</sup>Department of Nephrology, Beaumont Hospital, Dublin, Ireland; <sup>4</sup>Department of Nephrology,

### Factors associated with mortality

- 362 HD patients; 116 deaths
- 32% died over median of 2.6 years
- Factors:
  - Age
  - Lower albumin
  - Higher co-morbidity index
  - Higher symptoms (POS-S Renal)
  - Lower health status (EQ 5D and EQ VAS)

55% died over median 2.1 years if:

- age >60
- reported problems with self-care, ADLs, mobility
- Surprise Question (12 months) did NOT discriminate



External validation and clinical utility of a prediction model for 6-month mortality in patients undergoing hemodialysis for endstage kidney disease

Palliative Medicine

© The Author(s) 2017




Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269216317720832 journals.sagepub.com/home/pmj



Brian Forzley<sup>1,2</sup>, Lee Er<sup>3</sup>, Helen HL Chiu<sup>3</sup>, Ognjenka Djurdjev<sup>3</sup>, Dan Martinusen<sup>4</sup>, Rachel C Carson<sup>1,4</sup>, Gaylene Hargrove<sup>1,4</sup>, Adeera Levin<sup>1,3</sup> and Mohamud Karim<sup>1,5</sup>

# Cohen Model (Touchcalc): Survival across quartiles of predicted risk.




Lewis M. Cohen et al. CJASN 2010;5:72-79



# 6 month mortality prediction

- Canadian dialysis registry: background
  - Patients  $\geq$  75 the major group starting dialysis
    - 5 yr. survival only 27%
- Tested Cohen model in 374 HD patients
  - Mean age 68
  - 45% 'not surprised'
  - 127 (34%) died in 2 years from SQ
  - 11.5% died in first 6 months after SQ

Model performs well at group but not individual level



Discrimination in Canadian cohort not as strong as in original USA cohort

#### Authors' concern:

If the model over-estimates death risk then having conversations about withdrawal of dialysis may cause unnecessary distress & harm

But may be a good tool to aid initiating ACP discussions





# A Clinical Risk Prediction Tool for 6-Month Mortality After Dialysis Initiation Among Older Adults

James P. Wick, MSc,<sup>1</sup> Tanvir C. Turin, PhD, MBBS,<sup>2</sup> Peter D. Faris, PhD,<sup>1</sup> Jennifer M. MacRae, MSc, MD,<sup>1</sup> Robert G. Weaver, MSc,<sup>3</sup> Marcello Tonelli, SM MD,<sup>3</sup> Braden J. Manns, MSc, MD,<sup>1,3</sup> and Brenda R. Hemmelgarn, PhD, MD<sup>1,3</sup>

#### Alberta, Canada


#### 2,200 patients starting dialysis age <a></a>65; 17% died within 6 months

- Age ≥ 80
- Hospitalisation in prior 6 months
- CCF
- Starting dialysis 'early' (eGFR 10-15)
- Lymphoma, AF, metastatic cancer



**Figure 3.** Actual versus expected risk for 6-month mortality from the final logistic model.

#### Alberta risk model



#### Celine Foote, MD, PhD<sup>1,2</sup> Mark Woodward, PhD<sup>1,3,4</sup> Meg J. Jardine, MD, PhD<sup>1,2</sup>





# Scoring Risk Scores: Considerations Before Incorporating Clinical Risk Prediction Tools Into Your Practice

Am J Kidney Dis. 2017;69(5):555-557

Uncertainty about survival in elderly dialysis patients

Highlights that predictive tools (usually after dialysis has commenced) from one country may not be applicable in another

A score at time of decision making (dialysis or not) would be of more use


Clinicians need be guarded about applicability of any predictive tool to their patient

# Frailty Screening Tools for Elderly Patients Incident to Dialysis CJASN ePress. Published on July 17, 2017 as doi: 10.2215/CJN.11801116

Ismay N. van Loon,\*<sup>†‡</sup> Namiko A. Goto,<sup>§</sup> Franciscus T.J. Boereboom,\*<sup>†</sup> Michiel L. Bots,<sup>||</sup> Marianne C. Verhaar,<sup>‡</sup> and Marije E. Hamaker<sup>¶</sup> The Netherlands

- 123 incident dialysis patients age > 65 assessed by aged care specialist -3 to +2 weeks starting dialysis
- Average age 76; 75% HD; 20% diabetes; 64% men; 25% acute dialysis start
- Geriatric assessment vs. 6 Frailty screening tools used
- Specialist assessment : 75% Frail.
  - 34% impaired ADLs; 66% some form of cognitive impairment;
  - 35% severe co-morbidities
  - 31% depressed
- No frailty test performed well enough to replace geriatric assessment but the latter is time consuming

#### No Frailty measure can replace geriatric assessment



**Figure 1.** | Frailty screenings tools compared with the geriatric assessment (two or more impairments). Diagonal represents a random guess (*i.e.*, 50–50 chance). Fried, Fried Frailty Index; G8, Geriatric8; GFI, Groningen Frailty Indicator; ISAR-HP, Identification of Seniors at Risk-Hospitalized Patients; Q, frailty question; VMS, Veiligheidsmanagementsysteem (Hospital Safety Program criteria).

CJASN ePress. Published on July 17, 2017 as doi: 10.2215/CJN.11801116

# Survival without dialysis



# Comparative Survival among Older Adults with Advanced Kidney Disease Managed Conservatively Versus with Dialysis The Netherlands. CJASN. April. 2016


Wouter R. Verberne,\* A.B.M. Tom Geers,\* Wilbert T. Jellema,\* Hieronymus H. Vincent,\* Johannes J.M. van Delden,<sup>†</sup> and Willem Jan W. Bos\*

- Retrospective; single centre; 2004-14; age ≥70
- 107 chose conservative management (age 83);
  - 204 RRT (age 76), p<0.001</li>
- CM included nurses, dieticians, social workers
- Davies co-morbidity score assessed:
  - IHD, LV function, PVD, malignancy, diabetes, COPD, CT disease
- Mean GFR at decision time 15 in CM, 13 in RRT
- Co-morbidities similar (33% ≥3 co-morbidities; 75% heart disease)



## Survival advantage lost if ≥80 yrs. old

# Age ≥80 years





# Comparative Survival among Older Adults with Advanced Kidney Disease Managed Conservatively Versus with Dialysis The Netherlands. CJASN. April. 2016

Wouter R. Verberne,\* A.B.M. Tom Geers,\* Wilbert T. Jellema,\* Hieronymus H. Vincent,\* Johannes J.M. van Delden,<sup>†</sup> and Willem Jan W. Bos\*

#### Median survival in CM patients from time of modality choice = 18 months

- Brown et al. = 16 months
- Wong et al. = 23 months
- Kwok et al (2016) = 16 months
- Carson = 14 months
- Murtagh = 18 months

#### Survival advantage lost if ≥ 80 in this study

- Hussein et al. = similar
- Chandna et al. & Murtagh et al. = survival advantage lost if >75 and severe co-morbidity

# Conservative Management and End-of-Life Care in an Australian Cohort with ESRD Clin J Am Soc Nephrol 11: 2195–2203, 2016.

Rachael L. Morton,\* Angela C. Webster,<sup>†</sup> Kevin McGeechan,<sup>†</sup> Kirsten Howard,<sup>†</sup> Fliss E.M. Murtagh,<sup>‡</sup> Nicholas A. Gray,<sup>§</sup> Peter G. Kerr,<sup>||</sup> Michael J. Germain,<sup>¶</sup> and Paul Snelling\*\*

#### Abstract

**Background and objectives** We aimed to determine the proportion of patients who switched to dialysis after confirmed plans for conservative care and compare survival and end-of-life care among patients choosing conservative care with those initiating RRT.

PINOT study patients enrolled over 3 months 2009 followed over 3 years

From 66 Renal Units in Australia – dialysis, transplant, CM patients

102/721 (14%) conservative care – mean age 79 vs 61 yrs.

Table 2. Dialysis access creation and initiation during the 3-year follow-up period among 102 patients who chose conservative care at study baseline


Characteristic	n	Percent	95% Confidence Interval, %
First dialysis access created <sup>a</sup>			
Fistula/vascular catheter	7	7	2 to 12
Peritoneal dialysis catheter	3	3	1 to 8
No access	85	83	76 to 90
Unknown	7	7	2 to 12
Dialysis commenced			
Yes	8	8	3 to 13
No	87	85	77 to 91
Unrecorded	7	7	2 to 12
Primary reason for commencement of dialysis			
Symptom management	4	50	22 to 78
Time-limited trial of dialysis	3	38	14 to 69
Emergency/intensive care unit admission	1	12	2 to 47

<sup>a</sup>Dialysis access was created for ten of 102 patients; eight of these patients commenced dialysis.

8% commenced dialysis (5 died)

21% (vs. 4%) had a documented ACP

Supplemental Figure 1. Multivariable analysis of factors associated with 3-year mortality among 590 participants



Among the 247 who died, 57% CM received specialist Palliative Care vs. 26% RRT

## Summary – Australian data

- 1. <10% who choose CM switch to RRT in 3 years
- 2. 1 in 5 CN patients with ESKD (eGFR <15) still alive after 3 years
- 3. For whole cohort factors associated with death
  - Older Age
  - Low serum albumin at start
  - CM (vs. RRT)
- 4. Those managed with RRT who died less likely to receive Palliative Care except in last week of life
- 5. Most common cause of death in RRT was withdrawal from dialysis
- 6. 43% of Australian nephrology trainees feel well trained in RSC



## Survival with and without dialysis

ANZDATA Median Survival on Dialysis by Age\*

Age at start of dialysis	Median, years
75-84	3.3
85+	2.1

\*ANZDATA 2016

Non-dialysis - Mean age 82:

median survival 1.4 years

St. George hospital data

St George data : No Survival advantage with dialysis if:

- age >75; and
- 2 or more co-morbidities
   (one being CCF or IHD)

ABS expected survival from age 82 = 7.5 yrs. men, 9.9 yrs. women




CJASN ePress. Published on April 4, 2017 as doi: 10.2215/CJN.09740916

Ethics Series

### Time to Improve Informed Consent for Dialysis: An International Perspective

Frank Brennan,\*\* Cameron Stewart,\* Hannah Burgess,\* Sara N. Davison,<sup>§</sup> Alvin H. Moss,<sup>||¶</sup> Fliss E.M. Murtagh,\*\* Michael Germain,<sup>††</sup> Shelley Tranter,\* and Mark Brown\*










Figure 1. | The elements of a legally valid consent for dialysis.



### Challenges to Nephrologists re Consent

#### 1. Awareness

 Nephrologists' knowledge and understanding of the law of consent (for dialysis)

#### 2. Preparedness

- Nephrologists' willingness to expand consent conversations beyond mechanical aspects of dialysis, to include:
  - Prognosis
  - QOL
  - Aspects of life that matter most to the patient
  - The option of conservative non-dialysis management

#### Characteristics and Outcomes of In-Hospital Palliative Care Consultation among Patients with Renal Disease Versus Other Serious Illnesses

Clin J Am Soc Nephrol 12: 1085-1089, 2017.

Vanessa Grubbs,\*\* David O'Riordan,\* and Steve Pantilat\*

33,000 patients (USA) in hospital who had Palliative Care consult
3% (1050) for Renal patients, 97% other conditions – cancer, heart, lung, neuro
mean age both groups 72

Symptoms at	time of consult (moderate/severe), % (n)			
Pain		24.7 (118)	30.9 (4737)	0.004
Anxiety	D   1500   0.00D	14.9 (66)	15.3 (2184)	0.90
Nausea	Renal group LESS pain & SOB	5.9 (27)	5.9 (871)	>0.99
Dyspnea		30.5 (39)	41.6 (1862)	0.01

Significant increase in NFR status after consultation (30 to 69%)

#### Anxiety improved by Palliative Care consultation?

Table 2. Patient characteristics after palliative care consultation by condition prompting palliative care consultation					
Chamadariatia	Condition Prompting Palliative Care Consultation, % (n)				
Characteristic	Renal Disease	Other Serious Illnesses <sup>a</sup>	P Value		
Symptom improvement from first to second assessment <sup>b</sup>					
first to second assessment <sup>b</sup>					
Pain	66.7 (38)	76.6 (2056)	0.90		
Anxiety	92.0 (23)	66.0 (819)	< 0.01		
Nausea	71.4 (10)	78.4 (462)	0.50		
Dyspnea	69.2 (9)	68.0 (650)	0.90		
Family meetings			0.66		
No meetings	26.7 (249)	25.1 (7025)			
One meeting	45.3 (422)	45.4 (12,678)			
Two or more meetings	28.0 (261)	29.5 (8251)			
Discharged alive	78.7 (821)	77.4 (23,642)	0.34		
Referred to hospice	30.7 (210)	37.6 (7571)	< 0.001		

<sup>\*</sup>Other serious illnesses include cancer, heart disease, pulmonary disease, and neurologic disease.

Small numbers of moderate to severe symptoms in this renal cohort

Message from the study:

Renal patients in USA benefit as much as anyone else from Palliative Care consultation

<sup>&</sup>lt;sup>b</sup>Includes patients reporting moderate to severe symptoms at first assessment who report improvement by at least one category at the second assessment that occurred within 72 hours of the first assessment.

### Summary 2016 to 2017

- We have more data about survival
  - On dialysis
  - Off dialysis
    - Many Non-dialysis ESKD patients live longer than expected
- This should aid discussions
- We have predictive tools
  - Most only valid for individual patients at a local level
  - Common markers of poor prognosis
- Most patients on a non-dialysis pathway will not change to dialysis
- ACP remains difficult but is getting greater attention
- Palliative care consults worthwhile for renal patients

# Ethics and 'Post-progress'

'Post-progress' suggests that technical ability and more and more interventions, while they extend wanted life for many, also bring with them existential quandaries about one's own relationship to medicine, to suffering, to more life, and of the apparent control that can be exercised over the timing of death.

-Sharon R. Kaufman, Kaufman, S.R. **Ordinary Medicine.** Duke University Press, Chapel Hill, NC; 2015

